Literature DB >> 15048935

Effects of cyclin-dependent kinase-5 activity on apoptosis and tau phosphorylation in immortalized mouse brain cortical cells.

Shirley B Shelton1, Pavan Krishnamurthy, Gail V W Johnson.   

Abstract

Cyclin-dependent kinase-5 (CDK5), a unique CDK family member, is active primarily in the central nervous system (CNS). Previous studies suggest that CDK5 is proapoptotic and contributes to tau hyperphosphorylation and neurodegeneration in Alzheimer's disease. The objective of this study was to examine CDK5 effects on apoptotic progression and tau phosphorylation. Immortalized embryonic mouse brain cortical cells were used to establish a stable cell line that overexpressed wild-type human tau. In these studies, thapsigargin, which induces endoplasmic reticulum stress and can cause accumulation of misfolded proteins, was used to induce apoptosis. Caspase-3 activity and poly-(ADP-ribose)-polymerase (PARP) cleavage, as measures of apoptosis, were significantly increased 24 and 48 hr after thapsigargin treatment, and these events were unaffected by tau expression. Although transient coexpression of CDK5 and its activator, p25, increased CDK5 activity greater than tenfold, increases in caspase-3 activity in response to thapsigargin treatment were unaffected by the presence of CDK5/p25. Tau phosphorylation at the PHF-1 epitope, but not the Tau-1 epitope, was increased significantly in CDK5/p25-transfected cells compared to cells transfected with dominant negative CDK5 (DNCDK5). The PHF-1 epitope remained phosphorylated until 48 hr after thapsigargin treatment in the CDK5/p25-transfected cells. Over the course of apoptosis in this model, phosphorylation of the Tau-1 epitope was unaffected in cells transfected with DNCDK5, vector, or CDK5/p25. In summary, these results demonstrate that CDK5 does not have a significant impact on tau phosphorylation and thapsigargin-induced apoptosis in this neuronal cell model. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15048935     DOI: 10.1002/jnr.20051

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  7 in total

Review 1.  Tau as a therapeutic target for Alzheimer's disease.

Authors:  A Boutajangout; E M Sigurdsson; P K Krishnamurthy
Journal:  Curr Alzheimer Res       Date:  2011-09       Impact factor: 3.498

2.  A caspase cleaved form of tau is preferentially degraded through the autophagy pathway.

Authors:  Philip J Dolan; Gail V W Johnson
Journal:  J Biol Chem       Date:  2010-05-13       Impact factor: 5.157

3.  Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles.

Authors:  Antonella Caccamo; Salvatore Oddo; Lana X Tran; Frank M LaFerla
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

4.  Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease.

Authors:  Rodrigo A Quintanilla; Tori A Matthews-Roberson; Philip J Dolan; Gail V W Johnson
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

5.  Huperzine A provides neuroprotection against several cell death inducers using in vitro model systems of motor neuron cell death.

Authors:  Richelle A Hemendinger; Edward J Armstrong; Rafal Persinski; Julianne Todd; Jean-Luc Mougeot; Franklin Volvovitz; Jeffrey Rosenfeld
Journal:  Neurotox Res       Date:  2008-01       Impact factor: 3.911

6.  Immortalized cortical neurons expressing caspase-cleaved tau are sensitized to endoplasmic reticulum stress induced cell death.

Authors:  Tori A Matthews-Roberson; Rodrigo A Quintanilla; Huiping Ding; Gail V W Johnson
Journal:  Brain Res       Date:  2008-08-07       Impact factor: 3.252

7.  Indirubin-3'-monoxime suppresses amyloid-beta-induced apoptosis by inhibiting tau hyperphosphorylation.

Authors:  Shu-Gang Zhang; Xiao-Shan Wang; Ying-Dong Zhang; Qing Di; Jing-Ping Shi; Min Qian; Li-Gang Xu; Xing-Jian Lin; Jie Lu
Journal:  Neural Regen Res       Date:  2016-06       Impact factor: 5.135

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.